Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by IrishCanuckon Dec 04, 2020 11:54am
216 Views
Post# 32037314

RE:Updates from Dan

RE:Updates from DanMost in vivo toxicology studies don't take long and we have had six months pass since Phase 2 was released. I hope they initiated long term toxicology for carcinogenesis long before June or else we'll be waiting a few years... but considering Otenaproxesul is based on compounds naturally produced in the body for cell signalling you could very quickly reduce that parameter timeframe with any reasonable regulatory body. 

Some of the 9 studies could be run alongside each other, some can only be started based on the results of prior studies. I wonder what the cohort sizes are, but that last study he said would start "next week" fingers crossed it the last one. We could very easily see the end of these studies by the end of this month. 

As everything from the RS has been sorted out for the stock market now let's hope there is a news release on Monday. They have recently jampacked their website with information. I'm just as excited for ATB-352 updates as Otenaproxesul as both should move the needle, obviously Phase 3 being the catalyst
<< Previous
Bullboard Posts
Next >>